Adenovirus-mediated ING4/PTEN double tumor suppressor gene co-transfer modified by RGD enhances antitumor activity in human nasopharyngeal carcinoma cells

Wang,Yihong; Yang,Jicheng; Sheng,Weihua; Xie,Yufeng; Liu,Jisheng

doi:10.3892/ijo.2015.2822

Adenovirus-mediated ING4/PTEN double tumor suppressor gene co-transfer modified by RGD enhances antitumor activity in human nasopharyngeal carcinoma cells

Authors:
- Yihong Wang
- Jicheng Yang
- Weihua Sheng
- Yufeng Xie
- Jisheng Liu
View Affiliations

Affiliations: Department of ENT, The First Affiliated Hospital of Soochow University, Suzhou 215006, P.R. China, Cell and Molecular Biology Institute, College of Medicine, Soochow University, Suzhou 215006, P.R. China, Institute for Cancer Center Laboratory, The First Affiliated Hospital and Experiment Center of Soochow University, Suzhou 215006, P.R. China
Published online on: January 8, 2015 https://doi.org/10.3892/ijo.2015.2822
Pages: 1295-1303

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inhibitor of growth-4 (ING4) is a member of the inhibitor of growth (ING) family and acts as a tumor suppressor protein. PTEN is a phosphatase and shows potent and extensive antitumor activity. In this study, we constructed an RGD-modified bicistronic ING4/PTEN adenovirus (Ad.RGD-ING4-PTEN) and comprehensively investigated its effects following modification of the CNE human nasopharyngeal carcinoma cell line both in vitro and in vivo. We demonstrated that Ad.RGD-ING4-PTEN enhanced growth inhibition and apoptosis. Furthermore, expression of P21, Bax and cleaved caspase-3 was upregulated, while that of Bcl-2 and survivin was downregulated in CNE cells and CNE xenografted tumors. Moreover, Ad.RGD-ING4-PTEN treatment additively downregulated CD34, VEGF and microvessel density in subcutaneously (s.c.) xenografted CNE cell tumors. The enhanced antitumor activity generated by Ad.RGD-ING4-PTEN was closely associated with activation of the intrinsic and extrinsic apoptotic pathways and additive inhibition of tumor angiogenesis both in vitro and in vivo. On the basis of this evidence, it is believed that cancer gene therapy combining two tumor suppressors such as ING4 and PTEN can be used to establish an effective and novel therapeutic strategy for nasopharyngeal carcinoma and other cancers.

View Figures

View References

1	Chang ET and Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 15:1765–1777. 2006. View Article : Google Scholar : PubMed/NCBI
2	Guigay J: Advances in nasopharyngeal carcinoma. Curr Opin Oncol. 20:264–269. 2008. View Article : Google Scholar : PubMed/NCBI
3	Agulnik M and Epstein JB: Nasopharyngeal carcinoma: current management, future directions and dental implications. Oral Oncol. 44:617–627. 2008. View Article : Google Scholar
4	Tao Q and Chan AT: Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med. 9:1–24. 2007. View Article : Google Scholar : PubMed/NCBI
5	Ma BB, Hui EP and Chan AT: Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci. 99:1311–1318. 2008. View Article : Google Scholar : PubMed/NCBI
6	Schnell O, Krebs B, Wagner E, et al: Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol. 18:378–386. 2008. View Article : Google Scholar : PubMed/NCBI
7	Katayama K, Furuki R, Yokoyama H, et al: Enhanced in vivo gene transfer into the placenta using RGD fiber-mutant adenovirus vector. Biomaterials. 32:4185–4193. 2011. View Article : Google Scholar : PubMed/NCBI
8	Park J, Singha K, Son S, Kim J, Namgung R, Yun CO and Kim WJ: A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy. Cancer Gene Ther. 19:741–748. 2012. View Article : Google Scholar : PubMed/NCBI
9	O’Neill AM, Smith AN, Spangler EA, et al: Resistance of canine lymphoma cells to adenoviral infection due to reduced cell surface RGD binding integrins. Cancer Biol Ther. 11:651–658. 2011. View Article : Google Scholar
10	Shiseki M, Nagashima M, Pedeux RM, et al: p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res. 63:2373–2378. 2003.PubMed/NCBI
11	Ythier D, Larrieu D, Brambilla C, Brambilla E and Pedeux R: The new tumor suppressor genes ING: genomic structure and status in cancer. Int J Cancer. 123:1483–1490. 2008. View Article : Google Scholar : PubMed/NCBI
12	Palacios A, Moreno A, Oliveira BL, et al: The dimeric structure and the bivalent recognition of H3K4me3 by the tumor suppressor ING4 suggests a mechanism for enhanced targeting of the HBO1 complex to chromatin. J Mol Biol. 396:1117–1127. 2010. View Article : Google Scholar : PubMed/NCBI
13	Li J, Martinka M and Li G: Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis. 29:1373–1379. 2008. View Article : Google Scholar : PubMed/NCBI
14	Garkavtsev I, Kozin SV, Chernova O, et al: The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature. 428:328–332. 2004. View Article : Google Scholar : PubMed/NCBI
15	Liu Y, Yu L, Wang Y, Zhang Y, Wang Y and Zhang G: Expression of tumor suppressor gene ING4 in ovarian carcinoma is correlated with microvessel density. J Cancer Res Clin Oncol. 138:647–655. 2012. View Article : Google Scholar : PubMed/NCBI
16	Zeng ZL, Li FJ, Gao F, Sun DS and Yao L: Upregulation of miR-650 is correlated with down-regulation of ING4 and progression of hepatocellular carcinoma. J Surg Oncol. 107:105–110. 2013. View Article : Google Scholar
17	Xie Y, Sheng W, Miao J, Xiang J and Yang J: Enhanced antitumor activity by combining an adenovirus harboring ING4 with cisplatin for hepatocarcinoma cells. Cancer Gene Ther. 18:176–188. 2011. View Article : Google Scholar :
18	Zhao Y, Su C, Zhai H, Tian Y, Sheng W, Miao J and Yang J: Synergistic antitumor effect of adenovirus-mediated hING4 gene therapy and (125)I radiation therapy on pancreatic cancer. Cancer Lett. 316:211–218. 2012. View Article : Google Scholar
19	Ling C, Xie Y, Zhao D, Zhu Y, Xiang J and Yang J: Enhanced radiosensitivity of non-small-cell lung cancer (NSCLC) by adenovirus-mediated ING4 gene therapy. Cancer Gene Ther. 19:697–706. 2012. View Article : Google Scholar : PubMed/NCBI
20	Unoki M, Shen JC, Zheng ZM and Harris CC: Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility. J Biol Chem. 281:34677–34686. 2006. View Article : Google Scholar : PubMed/NCBI
21	Salmena L, Carracedo A and Pandolfi PP: Tenets of PTEN tumor suppression. Cell. 133:403–414. 2008. View Article : Google Scholar : PubMed/NCBI
22	Leslie NR and Foti M: Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol Sci. 32:131–140. 2011. View Article : Google Scholar : PubMed/NCBI
23	Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 8:627–644. 2009. View Article : Google Scholar : PubMed/NCBI
24	Leslie NR, Yang X, Downes CP and Weijer CJ: PtdIns(3,4,5) P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol. 17:115–125. 2007. View Article : Google Scholar : PubMed/NCBI
25	Putz U, Howitt J, Doan A, Goh CP, Low LH, Silke J and Tan SS: The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells. Sci Signal. 5:ra702012.PubMed/NCBI
26	Hopkins BD, Fine B, Steinbach N, et al: A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science. 341:399–402. 2013. View Article : Google Scholar : PubMed/NCBI
27	Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat. 36:169–180. 1995. View Article : Google Scholar : PubMed/NCBI
28	Wang W, Qin SK, Chen BA and Chen HY: Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma. World J Gastroenterol. 7:702–705. 2001.
29	Jung YS, Qian Y and Chen X: Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal. 22:1003–1012. 2010. View Article : Google Scholar : PubMed/NCBI
30	Blain SW: Switching cyclin D-Cdk4 kinase activity on and off. Cell Cycle. 7:892–898. 2008. View Article : Google Scholar : PubMed/NCBI
31	Zhou C, Li X, Du W, et al: Antitumor effects of ginkgolic acid in human cancer cell occur via cell cycle arrest and decrease the Bcl-2/Bax ratio to induce apoptosis. Chemotherapy. 56:393–402. 2010. View Article : Google Scholar : PubMed/NCBI
32	Lee JS, Jung WK, Jeong MH, Yoon TR and Kim HK: Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway. Int J Toxicol. 31:70–77. 2012. View Article : Google Scholar : PubMed/NCBI
33	Church DN and Talbot DC: Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep. 14:120–128. 2012. View Article : Google Scholar : PubMed/NCBI
34	Riedl SJ and Shi Y: Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 5:897–907. 2004. View Article : Google Scholar : PubMed/NCBI
35	Roskoski R Jr: Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol. 62:179–213. 2007. View Article : Google Scholar : PubMed/NCBI
36	Canavese M and Spaccapelo R: Protective or pathogenic effects of vascular endothelial growth factor (VEGF) as potential biomarker in cerebral malaria. Pathog Glob Health. 108:67–75. 2014. View Article : Google Scholar : PubMed/NCBI